Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.